New population of immune cells could play a role in multiple sclerosis

October 23, 2020

PHILADELPHIA - Multiple sclerosis (MS) is an autoimmune disorder that develops as immune cells attack the nervous system. T cells are a critical part of our immune system, with a complex array of subtypes - some drive the autoimmune response, while others try to suppress it.

A team of investigators at Thomas Jefferson University have characterized a new population of T cells called ThGM cells that produce granulocyte macrophage-colony-stimulating factor (GM-CSF), a chemical that contributes to the autoimmune response. They had previously shown that increased numbers of ThGM cells are found in the blood and brain of MS patients, indicating that these cells may contribute to the development of autoimmunity. However, very little is known about the genetic properties and function of ThGM cells, making it difficult to understand their role in MS. The team has now uncovered key defining features of these cells and how they behave in an animal model of MS, paving the way for future studies and potential therapies. The study was published in Science Immunology on October 23.

The researchers first sought to characterize the ThGM cells in healthy human subjects and in an animal model of MS. Using various genetic and biochemical techniques, they found that the ThGM cells were abundantly present, but interestingly, lacked the characteristic markers of other populations of T-cells.

"We found that the ThGM cells have a distinct genetic profile compared to other subsets of T cells," says senior author Abdolmohamad Rostami, MD, PhD, professor and Chairman of the department of Neurology at Sidney Kimmel Medical College - Thomas Jefferson University and Vickie and Jack Farber Institute for Neuroscience - Jefferson Health. "It appears that ThGM cells are coming from a distinct lineage or origin, and therefore we've been able to define a set of criteria for identifying these cells."

The researchers also found that in a mouse model for MS there are increased numbers of ThGM cells in the nervous system, similar to findings in human disease. They also found that the ThGM cells induced endephalomyelitis, or inflammation of the brain and spinal cord, a sign of disease development in this model of MS, lending further evidence that ThGM cells contribute to autoimmunity.

The team is now working on further characterizing the ThGM cells in humans. "Our findings have already given us important clues on what genetic markers and chemical profile make this subset of T cells unique," explains Dr. Rostami. "This could allow us to develop therapies that selectively target this population of T cells, while leaving other T cells intact and avoiding widespread immunosuppression."

"This study was made possible by a talented group of scientists, especially Javad Rasouli, a postdoctoral fellow in the lab, and Bogoljub Ciric, associate professor of neurology here at Jefferson," says Dr. Rostami.
The work was supported by NIH grants R01NS048435 and5R01AI124386.

By Karuna Meda

Article Reference:

Javad Rasouli, Giacomo Casella, Satoshi Yoshimura, Weifeng Zhang, Dan Xiao, James Garifallou, Michael V. Gonzalez, Alice Wiedeman, Anna Kus, Elisabeth R. Mari, Paolo Fortina, Hakon Hakonarson, S. Alice Long, Guang-Xian Zhang, Bogoljub Ciric, Abdolmohamad Rostami, "A distinct GM-CSF+ T helper cell subset requires T-bet to adopt a TH1 phenotype and promote neuroinflammation", Science Immunology, 2020

Media Contact:
Karuna Meda

Thomas Jefferson University

Related Multiple Sclerosis Articles from Brightsurf:

New therapy improves treatment for multiple sclerosis
A new therapy that binds a cytokine to a blood protein shows potential in treating multiple sclerosis, and may even prevent it.

'Reelin' in a new treatment for multiple sclerosis
In an animal model of multiple sclerosis (MS), decreasing the amount of a protein made in the liver significantly protected against development of the disease's characteristic symptoms and promoted recovery in symptomatic animals, UTSW scientists report.

Not all multiple sclerosis-like diseases are alike
Scientists say some myelin-damaging disorders have a distinctive pathology that groups them into a unique disease entity.

New therapeutic options for multiple sclerosis in sight
Strategies for treating multiple sclerosis have so far focused primarily on T and B cells.

Diet has an impact on the multiple sclerosis disease course
The short-chain fatty acid propionic acid influences the intestine-mediated immune regulation in people with multiple sclerosis (MS).

The gut may be involved in the development of multiple sclerosis
It is incompletely understood which factors in patients with multiple sclerosis act as a trigger for the immune system to attack the brain and spinal cord.

Slowing the progression of multiple sclerosis
Over 77,000 Canadians are living with multiple sclerosis, a disease whose causes still remain unknown.

7T MRI offers new insights into multiple sclerosis
Investigators from Brigham and Women's Hospital have completed a new study using 7 Tesla (7T) MRI -- a far more powerful imaging technology -- to further examine LME in MS patients

How to improve multiple sclerosis therapy
Medications currently used to treat multiple sclerosis (MS) can merely reduce relapses during the initial relapsing-remitting phase.

Vaccinations not a risk factor for multiple sclerosis
Data from over 12,000 multiple sclerosis (MS) patients formed the basis of a study by the Technical University of Munich (TUM) which investigated the population's vaccination behavior in relation to MS.

Read More: Multiple Sclerosis News and Multiple Sclerosis Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to